Outlining the steps to a payment approach for Medicare Part D drugs that provides savings for patients.
Matthew Majewski
Advertisement
Articles by Matthew Majewski
There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.
Advertisement
Latest Updated Articles
- Reducing Prescription Drug Costs for Seniors: The ABCs of ASP for Part D
Published: December 15th 2020 | Updated:
Pricing for Rare Disease and Curative Therapies: What’s Fair?Published: June 2nd 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
3
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
4
Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization
5
